CHAMPIONS ONCOLOGY, INC.
CSBR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CSBR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CSBR
Champions Oncology, Inc. is a technology-enabled research organization that provides oncology drug development services via its TumorGraft Platform and Lumin bioinformatics SaaS, operating with limited cash and a going concern risk.
Key risk: Going concern risk
Market Cap
$68.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Apr 30, 2026.
Champions Oncology, Inc. is a technology-enabled research organization that provides oncology drug development services via its TumorGraft Platform and Lumin bioinformatics SaaS, operating with limited cash and a going concern risk.
- Champions Oncology is a technology-enabled research organization focused on creating transformative technology for drug development [sec_mda · as of 2025-07-23].
- The company's TumorGraft Technology Platform is a comprehensive bank of unique, well-characterized models used to predict oncology drug efficacy for pharmaceutical and biotech clients [sec_mda · as of 2024-12-16].
- It offers Lumin Bioinformatics, an oncology data-driven SaaS program that leverages a large datacenter with analytics and AI for computational cancer research [sec_mda · as of 2024-12-16].
- As of 2026-04-30, the company reported cash and equivalents of $4.9M, shareholders' equity of $3.9M, and no debt [latest reported financials].
- The company has a history of net losses and working capital deficits, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-03-17].
What works
- The TumorGraft Platform provides select services to pharmaceutical and biotechnology companies, facilitating drug discovery with lower costs and increased speed [sec_mda · as of 2024-12-16].
- Lumin Bioinformatics offers a robust tool for computational cancer research, combining a large Datacenter with analytics and AI [sec_mda · as of 2024-12-16].
- The company regularly evaluates strategic options to create additional value, including potential spin-out transactions, licensing opportunities, or capital raises [sec_mda · as of 2026-07-27].
What to weigh
- The company has a history of net losses and working capital deficits, raising substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-03-17].
- Cash and equivalents are limited to $4.9M as of 2026-04-30, which may constrain operations and growth initiatives [latest reported financials].
- Research and development costs are expensed as incurred, contributing to ongoing financial losses [sec_mda · as of 2026-07-27].
From the filings
Quoted directly from source documents.
The company's TumorGraft Platform is used to predict oncology drug efficacy.
“Utilizing our TumorGraft Technology Platform (the "Platform"), a comprehensive bank of unique, well characterized models, we provide select services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. By performing studies to predict the efficacy of oncology drugs, our Platform facilitates drug discovery with lower costs and increased speed of drug development as well as increased adoption of existing drugs.”
SEC MD&A · December 16, 2024
The company has substantial doubt about its ability to continue as a going concern.
“The following conditions raised substantial doubt about our ability to continue as a going concern: a history of net losses, working capital d”
SEC MD&A · March 17, 2025
The company offers Lumin Bioinformatics as a SaaS program.
“We offer Lumin Bioinformatics ("Lumin"), an oncology data-driven Software as a Service ("SaaS") program. Our Lumin software contains comprehensive information derived from our research services and clinical studies. Lumin leverages our large Datacenter coupled with analytics and artificial intelligence to”
SEC MD&A · December 16, 2024
The company regularly evaluates strategic options for its drug discovery business.
“We regularly evaluate strategic options to create additional value from our drug discovery business, which may include, but are not limited to, potential spin-out transactions, licensing opportunities, or capital raises.”
SEC MD&A · July 27, 2026
Risks & what to watch (3)›
Key risks
- Going concern risk — History of net losses and working capital deficits raise substantial doubt about ability to continue as a going concern [sec_mda · as of 2025-03-17].
- Limited cash runway — Only $4.9M in cash as of 2026-04-30, which may not sustain operations without additional financing [latest reported financials].
- Dependence on strategic options — Future value creation relies on uncertain spin-outs, licensing, or capital raises [sec_mda · as of 2026-07-27].
What to watch
- Monitor the company's ability to raise additional capital or execute strategic transactions such as spin-outs or licensing deals [sec_mda · as of 2026-07-27].
- Watch for updates on the adoption and revenue generation from the TumorGraft Platform and Lumin Bioinformatics services [sec_mda · as of 2024-12-16].
- Track any changes in the going concern status or improvements in working capital in future filings [sec_mda · as of 2025-03-17].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CHAMPIONS ONCOLOGY, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CHAMPIONS ONCOLOGY, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$24.1M
| Holder | Shares | Value |
|---|---|---|
| battery management corp. | 2,421,673 | $13.9M |
| vanguard capital management llc | 599,040 | $3.4M |
| tocqueville asset management l.p. | 319,674 | $1.8M |
| morgan stanley | 242,300 | $1.4M |
| renaissance technologies llc | 145,539 | $837K |
| blackrock, inc. | 123,900 | $712K |
| geode capital management, llc | 77,177 | $444K |
| northern trust corp | 45,932 | $264K |
| hightower advisors, llc | 35,158 | $202K |
| vanguard fiduciary trust co | 32,992 | $190K |
Showing top 10 of 24 institutional holders of CHAMPIONS ONCOLOGY, INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 1.2%
- Days to cover
- 12.3
- Shares short
- 83,705
- Daily short volume (Jun 17, 2026)
- 34.4%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CSBR short interestGovernance
Frequently asked questions
What is the AI investment thesis for CHAMPIONS ONCOLOGY, INC.?
Champions Oncology, Inc. is a technology-enabled research organization that provides oncology drug development services via its TumorGraft Platform and Lumin bioinformatics SaaS, operating with limited cash and a going concern risk.
Who is the CEO of CHAMPIONS ONCOLOGY, INC.?
Mr. Robert Brainin is the chief executive officer of CHAMPIONS ONCOLOGY, INC. (CSBR).
Where is CHAMPIONS ONCOLOGY, INC. headquartered?
CHAMPIONS ONCOLOGY, INC. (CSBR) is headquartered in Hackensack, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.